Loading
Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.
Jason Luke was principal investigator of KEYNOTE-716, which showed adjuvant pembrolizumab reduces recurrence and distant metastasis in resected stage IIB and IIC melanoma, the first adjuvant immunotherapy approval in stage II disease. He runs one of the largest early-phase immunotherapy programmes in the United States and studies mechanisms of primary resistance to checkpoint blockade. He is active in SITC leadership.
| Title | Journal | Year |
|---|---|---|
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716) | Lancet | 2022 |
| Targeted agents and immunotherapies: optimizing outcomes in melanoma | Nature Reviews Clinical Oncology | 2017 |
Shares UPMC Hillman Cancer Center, Stage IIB and IIC melanoma, Melanoma and the tags melanoma, adjuvant.
Shares Nature Reviews Clinical Oncology, PD-1, Melanoma, Pembrolizumab and the tag melanoma.
Shares PD-1, Melanoma, Pembrolizumab, Immune checkpoint inhibitors and the tags melanoma, adjuvant.
Shares KEYNOTE-716, Stage IIB and IIC melanoma, Pembrolizumab.
Shares KEYNOTE-716, Stage IIB and IIC melanoma, Melanoma, Immune checkpoint inhibitors.
Shares PD-1, Melanoma, Pembrolizumab, Immune checkpoint inhibitors and the tag melanoma.
Shares Stage IIB and IIC melanoma, Melanoma and the tag melanoma.
Shares PD-1, Melanoma, Immune checkpoint inhibitors and the tag melanoma.